We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALKS icon
276
Alkermes
ALKS
$6.56B
– –
-46,400
Closed -$1.64M –
ANNX icon
277
Annexon
ANNX
$696M
– –
-55,000
Closed -$305K –
APLS icon
278
DELISTED
Apellis Pharmaceuticals
APLS
– –
-72,500
Closed -$2.92M –
AQST icon
279
Aquestive Therapeutics
AQST
$579M
– –
-10,000
Closed -$41.5K –
ARCT icon
280
Arcturus Therapeutics
ARCT
$316M
– –
-15,000
Closed -$116K –
JBIO icon
281
Jade Biosciences
JBIO
$855M
– –
-20,000
Closed -$281K –
BCAB icon
282
DELISTED
BIOATLA INC
BCAB
– –
-4,562
Closed -$36.7K –
BEAM icon
283
Beam Therapeutics
BEAM
$2.44B
– –
-1,446,375
Closed -$34.5M –
BLTE icon
284
Belite Bio
BLTE
$6.15B
– –
-26,880
Closed -$4.29M –
BMY icon
285
Bristol-Myers Squibb
BMY
$121B
– –
-17,500
Closed -$1.06M –
CGEM icon
286
Cullinan Oncology
CGEM
$878M
– –
-50,000
Closed -$711K –
CLOV icon
287
Clover Health Investments
CLOV
$2.54B
– –
-40,000
Closed -$70.4K –
CNTA
288
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-38,566
Closed -$1.53M –
CORT icon
289
Corcept Therapeutics
CORT
$12.6B
– –
-8,000
Closed -$322K –
CORZ icon
290
Core Scientific
CORZ
$4.34B
– –
-30,000
Closed -$449K –
CRWD icon
291
CrowdStrike
CRWD
$255B
– –
-2,560
Closed -$250K –
DAWN icon
292
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-49,923
Closed -$1.07M –
DNTH icon
293
Dianthus Therapeutics
DNTH
$4.18B
– –
-55,000
Closed -$4.62M –
DSGN icon
294
Design Therapeutics
DSGN
$609M
– –
-10,000
Closed -$106K –
ELAN icon
295
Elanco Animal Health
ELAN
$11.3B
– –
-20,000
Closed -$479K –
ERAS icon
296
Erasca
ERAS
$5.14B
– –
-10,000
Closed -$162K –
ESPR icon
297
DELISTED
Esperion Therapeutics
ESPR
– –
-21,400
Closed -$58.6K –
FDMT icon
298
4D Molecular Therapeutics
FDMT
$674M
– –
-116,712
Closed -$1.09M –
KYNB icon
299
Kyntra Bio
KYNB
$22.6M
– –
-10,469
Closed -$71K –
FOLD icon
300
DELISTED
Amicus Therapeutics
FOLD
– –
-105,000
Closed -$1.52M –
10 11
12
13 14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.